Price to Earnings (P/E)
since 2012
Paying user area
Try for free
AbbVie Inc. pages available for free this week:
- Common-Size Balance Sheet: Assets
- Analysis of Profitability Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Enterprise Value (EV)
- Price to FCFE (P/FCFE)
- Selected Financial Data since 2012
- Debt to Equity since 2012
- Price to Operating Profit (P/OP) since 2012
- Analysis of Debt
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to AbbVie Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
AbbVie Inc., P/E, long-term trends, calculation
| P/E | = | Share price1, 2, 3 | ÷ | Earnings per share1 (EPS) | EPS1 | = | Net earnings attributable to AbbVie Inc.1 (in millions) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 14, 2025 | = | ÷ | = | ÷ | |||||||
| Feb 20, 2024 | = | ÷ | = | ÷ | |||||||
| Feb 17, 2023 | = | ÷ | = | ÷ | |||||||
| Feb 18, 2022 | = | ÷ | = | ÷ | |||||||
| Feb 19, 2021 | = | ÷ | = | ÷ | |||||||
| Feb 21, 2020 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2019 | = | ÷ | = | ÷ | |||||||
| Feb 16, 2018 | = | ÷ | = | ÷ | |||||||
| Feb 17, 2017 | = | ÷ | = | ÷ | |||||||
| Feb 19, 2016 | = | ÷ | = | ÷ | |||||||
| Feb 20, 2015 | = | ÷ | = | ÷ | |||||||
| Feb 21, 2014 | = | ÷ | = | ÷ | |||||||
| Mar 15, 2013 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of AbbVie Inc. Annual Report.
- Share Price
- The share price exhibited an overall upward trend from 38.5 US dollars in March 2013 to 192.87 US dollars by February 2025. There were periods of fluctuation, notably a peak in February 2018 at 118.6 US dollars followed by a decline to 79.41 US dollars in February 2019. Subsequently, the share price recovered and increased steadily, reaching its highest value in the most recent period. This pattern indicates general market confidence with intermittent volatility.
- Earnings Per Share (EPS)
- The EPS figures displayed considerable volatility throughout the periods analyzed. Beginning at 3.34 US dollars in March 2013, EPS declined significantly by February 2015 to 1.11 US dollars, rebounded in the following years, with peaks at 6.53 US dollars in February 2022 and 6.69 US dollars in February 2023. However, the latest periods show a decline to 2.75 and then 2.42 US dollars. This inconsistent EPS performance suggests variability in profitability or earnings quality over time.
- Price-to-Earnings (P/E) Ratio
- The P/E ratio exhibited wide fluctuations, ranging from a low of 11.51 in March 2013 to a peak of 79.59 in February 2025. The ratio showed substantial spikes corresponding to periods of relatively low EPS or increased share prices, such as in February 2015 (55.08), February 2024 (63.84), and February 2025 (79.59). These elevated P/E ratios indicate higher market valuations relative to earnings, which may reflect investor expectations for growth or temporary misalignments between price and earnings.
- Overall Analysis
- The data reveals a complex relationship among share price, earnings per share, and valuation multiples. While the share price has experienced robust growth over the analyzed period, EPS has shown inconsistency, reflecting fluctuations in earnings performance. The corresponding P/E ratios have therefore varied significantly, at times indicating potentially overvalued market conditions or investor optimism despite earnings variability. This pattern suggests that external factors beyond earnings, such as market sentiment or growth prospects, could have influenced investor behavior and pricing.
Comparison to Competitors
AbbVie Inc., P/E, long-term trends, comparison to competitors
| AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 14, 2025 | ||||||||||||
| Feb 20, 2024 | ||||||||||||
| Feb 17, 2023 | ||||||||||||
| Feb 18, 2022 | ||||||||||||
| Feb 19, 2021 | ||||||||||||
| Feb 21, 2020 | ||||||||||||
| Feb 27, 2019 | ||||||||||||
| Feb 16, 2018 | ||||||||||||
| Feb 17, 2017 | ||||||||||||
| Feb 19, 2016 | ||||||||||||
| Feb 20, 2015 | ||||||||||||
| Feb 21, 2014 | ||||||||||||
| Mar 15, 2013 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
AbbVie Inc., P/E, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| AbbVie Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 14, 2025 | ||
| Feb 20, 2024 | ||
| Feb 17, 2023 | ||
| Feb 18, 2022 | ||
| Feb 19, 2021 | ||
| Feb 21, 2020 | ||
| Feb 27, 2019 | ||
| Feb 16, 2018 | ||
| Feb 17, 2017 | ||
| Feb 19, 2016 | ||
| Feb 20, 2015 | ||
| Feb 21, 2014 | ||
| Mar 15, 2013 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).
Comparison to Industry (Health Care)
AbbVie Inc., P/E, long-term trends, comparison to industry (health care)
| AbbVie Inc. | Health Care | |
|---|---|---|
| Feb 14, 2025 | ||
| Feb 20, 2024 | ||
| Feb 17, 2023 | ||
| Feb 18, 2022 | ||
| Feb 19, 2021 | ||
| Feb 21, 2020 | ||
| Feb 27, 2019 | ||
| Feb 16, 2018 | ||
| Feb 17, 2017 | ||
| Feb 19, 2016 | ||
| Feb 20, 2015 | ||
| Feb 21, 2014 | ||
| Mar 15, 2013 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).